Citations

Showing 10 of 108135 citations.

BRCA1-BARD1 regulates transcription through modulating topoisomerase IIβ
Bunch, Heeyoun , Jeong, Jaehyeon , Kang, Keunsoo , Jo, Doo Sin , Cong, Anh , Kim, Deukyeong, Chen, Benjamin P.C. , Schellenberg, Matthew J. , Calderwood, Stuart K. , Cong, Anh T Q, Calderwood, Stuart K , Cong, Anh T Q , Kim, Donguk , Cho, Dong‐Hyung , Lee, You Mie

Mayo Clinic

Open Biology | October 6, 2021 | Volume: 11 | Issue: 10 | Pages: No page available

10.1098/rsob.210221 | PMID 34610268 Get It

RNA polymerase II (Pol II)-dependent transcription in stimulus-inducible genes requires topoisomerase IIβ (TOP2B)-mediated DNA strand break and the activation of DNA damage response signalling in humans. Here, we report a novel function of the breast cancer 1 (BRCA1)-BRCA1-associated ring domain 1 (BARD1) complex in this process. We found that BRCA1 is phosphorylated at S1524 by the kinases ataxia-telangiectasia mutated and ATR during gene activation, and that this event is important for productive transcription. Our biochemical and genomic analyses showed that the BRCA1-BARD1 complex interacts with TOP2B in the EGR1 transcription start site and in a large number of protein-coding genes. Intriguingly, the BRCA1-BARD1 complex ubiquitinates TOP2B, which stabilizes TOP2B binding to DNA while BRCA1 phosphorylation at S1524 controls the TOP2B ubiquitination by the complex. Together, these findings suggest the novel function of the BRCA1-BARD1 complex in the regulation of TOP2B and Pol II-mediated gene expression.
Challenges in Translating Clinical Metabolomics Data Sets from the Bench to the Bedside
Ulmer, Candice Z. , Hines, Jolaine, Maus, Anthony , Singh, Ravinder J.

Mayo Clinic

Clinical Chemistry | October 6, 2021 | Volume: 67 | Issue: 12 | Pages: 1581-1583

10.1093/clinchem/hvab210 | PMID 34718477 Get It

Real-Time Ultrasound Imaging of the Tear Trough: Lessons Learned From Functional Anatomy
Calomeni, Mariana, Alfertshofer, Michael , Frank, Konstantin , Dennison, Rebekah, Bravo, Bruna Felix, Velthuis, Peter J. , Cotofana, Sebastian , Bihun, Rebekah , Elias, Mariana Calomeni , Alfertshofer, Michael , Bravo, Bruna , Cotofana, Sebastian , Frank, Konstantin , Moellhoff, Nicholas , Schelke, Leonie , Green, Jeremy B. , Bihun, Rebekah J.

Mayo Clinic

Aesthetic Surgery Journal | October 6, 2021 | Volume: 42 | Issue: 5 | Pages: 518-526

10.1093/asj/sjab351 | PMID 34610093 Get It

AbstractBackgroundThe tear trough is one of the most challenging facial regions for soft-tissue filler injections. A thorough understanding of the underlying facial, muscular, and vascular anatomy is crucial to perform safe and effective tear trough injectable treatments.ObjectivesThe authors sought to evaluate the location and function of the angular vein in the tear trough in 3 different facial expressions: repose, smiling, and max. orbicularis oculi contraction.MethodsTwenty study participants with a mean age of 48.3 years and mean BMI of 24.5 kg/m2 were investigated via functional ultrasound imaging. The diameter of the angular vein and the velocity and direction of venous blood flow were analyzed in repose, smiling, and during max. orbicularis oculi contraction.ResultsThe angular vein was identified in 100% of the cases to travel inside the orbicularis oculi muscle (intra-muscular course) within the tear trough, whereas the angular artery was not identified in this location. The distance between the angular vein and the inferior orbital rim was (lateral to medial): 4.6 mm, 4.5 mm, 3.9 mm, and 3.8 mm. The caudally directed blood flow was in repose 10.2 cm/s and was 7.3 cm/s at max. orbicularis oculi muscle contraction; however, no blood flow was detectable during smiling.ConclusionsThe diameter and the venous blood flow of the angular vein varied between the 3 tested facial expressions. Based on these anatomical findings, the deep injection approach to the tear trough is recommended due to the intramuscular course of the angular vein.
Association Between Structural Change Over Eighteen Months and Subsequent Symptom Change in Middle‐Aged Patients Treated for Meniscal Tear
Katz, Jeffrey N. , Collins, Jamie E. , Marx, Robert G. , Mandl, Lisa A. , Levy, Bruce A. , Wright, Rick W. , Jarraya, Mohamed , MacFarlane, Lindsey A. , Chang, Yuchiao , Mandl, Lisa A , MacFarlane, Lindsey A , Losina, Elena , Collins, Jamie E , Katz, Jeffrey N , Jones, Morgan H. , Spindler, Kurt P , Marx, Robert G. , Guermazi, Ali , Losina, Elena

Mayo Clinic

Arthritis Care & Research | October 5, 2021 | Volume: 75 | Issue: 2 | Pages: 340-347

10.1002/acr.24796 | PMID 34606692 Get It

ObjectiveMiddle‐aged subjects with meniscal tear treated with arthroscopic partial meniscectomy (APM) experience greater progression of damage to joint structures on imaging than subjects treated nonoperatively. It is unclear whether these changes are clinically relevant. The goal of this study was to assess whether worsening in magnetic resonance imaging (MRI)–assessed tissue damage over 18 months leads to subsequent worsening in knee pain over the subsequent 3.5 years.MethodsWe used data from the Meniscal Tear in Osteoarthritis Research (MeTeOR) trial of APM versus physical therapy for subjects ages ≥45 years with knee pain, cartilage damage, and meniscal tear. We assessed whether change in cartilage surface area damage score (and other structural measures) from baseline to 18 months, assessed on MRI with the MRI Osteoarthritis Knee Score (MOAKS) system, was associated with change in Knee Injury and Osteoarthritis Outcome Score (KOOS) pain score (range 0–100; 100 = worst) from 18 to 60 months.ResultsThe primary analysis included 168 subjects with complete MRI data at baseline and 18 months and KOOS data at 18 and 60 months. We did not observe clinically important associations between change in cartilage surface area score between baseline and 18 months and change in pain scores from 18 to 60 months. Pain scores in the worst tertile for cartilage surface area damage score progression worsened by 0.45 points more than in the best tertile (95% confidence interval –4.45, 5.35). Similarly, we did not observe clinically important associations between changes in bone marrow lesions, osteophytes, or synovitis and subsequent pain.ConclusionWe did not observe clinically important associations between early changes in cartilage damage and other structural measures and worsening in pain over the subsequent 3.5 years. Further follow‐up is required to assess this association over a longer follow‐up period.
Low frequency novel interictal EEG biomarker for localizing seizures and predicting outcomes
Lundstrom, Brian N. , Brinkmann, Benjamin H. , Lundstrom, Brian Nils , Brinkmann, Benjamin H , Worrell, Gregory A.

Mayo Clinic

Brain Communications | October 5, 2021 | Volume: 3 | Issue: 4 | Pages: No page available

10.1093/braincomms/fcab231 | PMID 34704030 Get It

Abstract Localizing hyperexcitable brain tissue to treat focal seizures remains challenging. We want to identify the seizure onset zone from interictal EEG biomarkers. We hypothesize that a combination of interictal EEG biomarkers, including a novel low frequency marker, can predict mesial temporal involvement and can assist in prognosis related to surgical resections. Interictal direct current wide bandwidth invasive EEG recordings from 83 patients implanted with 5111 electrodes were retrospectively studied. Logistic regression was used to classify electrodes and patient outcomes. A feed-forward neural network was implemented to understand putative mechanisms. Interictal infraslow frequency EEG activity was decreased for seizure onset zone electrodes while faster frequencies such as delta (2–4 Hz) and beta-gamma (20–50 Hz) activity were increased. These spectral changes comprised a novel interictal EEG biomarker that was significantly increased for mesial temporal seizure onset zone electrodes compared to non-seizure onset zone electrodes. Interictal EEG biomarkers correctly classified mesial temporal seizure onset zone electrodes with a specificity of 87% and positive predictive value of 80%. These interictal EEG biomarkers also correctly classified patient outcomes after surgical resection with a specificity of 91% and positive predictive value of 87%. Interictal infraslow EEG activity is decreased near the seizure onset zone while higher frequency power is increased, which may suggest distinct underlying physiologic mechanisms. Narrowband interictal EEG power bands provide information about the seizure onset zone and can help predict mesial temporal involvement in seizure onset. Narrowband interictal EEG power bands may be less useful for predictions related to non-mesial temporal electrodes. Together with interictal epileptiform discharges and high-frequency oscillations, these interictal biomarkers may provide prognostic information prior to surgical resection. Computational modelling suggests changes in neural adaptation may be related to the observed low frequency power changes.
Antiplatelet therapy and outcome in COVID-19: the Health Outcome Predictive Evaluation Registry
Santoro, Francesco , Núñez‐Gil, Iván J. , Vitale, Enrica , Viana‐Llamas, María C. , Reche-Martínez, Begoña, Romero-Pareja, Rodolfo, Guzman, Gisela Feltez, Rozas, Inmaculada Fernández, Uribarri, Aitor , Becerra‐Muñoz, Víctor Manuel , Alfonso‐Rodríguez, Emilio , García-Aguado, Marcos, Huang, Jia , Ortega-Armas, María Elizabeth , Prieto, Juan Fortunato García, Mulet, Alba , Raposeiras‐Roubín, Sergio , Mendez, Jorge Luis Jativa , Paeres, Carolina Espejo, Albarrán, Adrián Rodríguez, Marı́n, Francisco , Akın, İbrahim , Cortese, Bernardo , Macaya, Carlos , Nuñez-Gil, Ivan Javier , Corral Rubio, Eva Maria , Raposeiras-Roubin, Sergio , Guerra, Federico , Akin, Ibrahim , Cortese, Bernardo , Ramakrishna, Harish , Brunetti, Natale Daniele , Santoro, Francesco , Marín, Francisco , Viana-Llamas, María C , Becerra-Muñoz, Víctor , Uribarri, Aitor , Guzmãn, Gisela Feltes, Ugo, Fabrizio , Bianco, Matteo , Fernández‐Ortíz, Antonio

Mayo Clinic

Heart | October 5, 2021 | Volume: 108 | Issue: 2 | Pages: 130-136

10.1136/heartjnl-2021-319552 | PMID 34611045 Get It

Background Standard therapy for COVID-19 is continuously evolving. Autopsy studies showed high prevalence of platelet-fibrin-rich microthrombi in several organs. The aim of the study was therefore to evaluate the safety and efficacy of antiplatelet therapy (APT) in hospitalised patients with COVID-19 and its impact on survival. Methods 7824 consecutive patients with COVID-19 were enrolled in a multicentre international prospective registry (Health Outcome Predictive Evaluation-COVID-19 Registry). Clinical data and in-hospital complications were recorded. Data on APT, including aspirin and other antiplatelet drugs, were obtained for each patient. Results During hospitalisation, 730 (9%) patients received single APT (93%, n=680) or dual APT (7%, n=50). Patients treated with APT were older (74±12 years vs 63±17 years, p<0.01), more frequently male (68% vs 57%, p<0.01) and had higher prevalence of diabetes (39% vs 16%, p<0.01). Patients treated with APT showed no differences in terms of in-hospital mortality (18% vs 19%, p=0.64), need for invasive ventilation (8.7% vs 8.5%, p=0.88), embolic events (2.9% vs 2.5% p=0.34) and bleeding (2.1% vs 2.4%, p=0.43), but had shorter duration of mechanical ventilation (8±5 days vs 11±7 days, p=0.01); however, when comparing patients with APT versus no APT and no anticoagulation therapy, APT was associated with lower mortality rates (log-rank p<0.01, relative risk 0.79, 95% CI 0.70 to 0.94). On multivariable analysis, in-hospital APT was associated with lower mortality risk (relative risk 0.39, 95% CI 0.32 to 0.48, p<0.01). Conclusions APT during hospitalisation for COVID-19 could be associated with lower mortality risk and shorter duration of mechanical ventilation, without increased risk of bleeding. Trial registration number NCT04334291.
The Effects of Topical Timolol and Latanoprost on Calculated Ocular Perfusion Pressure in Nonglaucomatous Volunteers
Kolli, Ajay , Toris, Carol B. , Reed, David M. , Gilbert, Jesse, Sit, Arthur J. , Gulati, Vikas , Kazemi, Arash , Fan, Shan , Moroi, Sayoko E. , Moroi, Sayoko E , Sit, Arthur J , Musch, David C.

Mayo Clinic

Journal of Ocular Pharmacology and Therapeutics | October 5, 2021 | Volume: 37 | Issue: 10 | Pages: 565-574

10.1089/jop.2021.0068 | PMID 34610254 Get It

A Plan for Emergency Shutdown and Reopening for a Consortium of Biobanks
Schmelz, Monika , Sanderson, Micheline , Humeida, Razan, Cloete, Melissa, Mims, Martha P., Leong, Alan, Wisner, Lee, Silver, Sylvia , Silver, Sylvia , Castro, Patricia D. , Leong, Alan

Mayo Clinic

Biopreservation and Biobanking | October 5, 2021 | Volume: 19 | Issue: 5 | Pages: 394-398

10.1089/bio.2021.0038 | PMID 34610247 Get It

Background: The AIDS and Cancer Specimen Resource (ACSR) is a network of four regional biospecimen repositories and a technical core in the United States and South Africa. Its mission is to acquire, store, and distribute HIV-associated malignancy specimens and related clinical data to support translational research. At the outset of the COVID-19 pandemic, it became apparent that existing ACSR Standard Operating Procedures (SOPs) were not sufficient to ensure long-term maintenance and integrity of inventories during periods of extended shutdown. The ACSR needed an administrative SOP for situations pertaining to epidemics/pandemics. The ACSR Quality Working Group (QWG), comprised of representatives from each of the five ACSR sites and an external member who directs a large university medical center biorepository, addressed the issue. Methods: To understand the individual problems the sites faced, questions were developed to query each of the six QWG sites' contingency plans to cover this type of emergency, the amount of work allowed onsite and by whom, the challenges sites experienced, and the lessons learned to assist with future similar situations, while remaining consistent with the existing IRB protocols. Results: Reported challenges spanned all activities of classical biobanks and differed within the geographical locations of the sites and the local COVID-19 infection rate. Review of the responses to the questions revealed that the general shutdown of society external to the biorepositories presented them with a homogeneous collection of problems, limitations, and needs. This led to creating an SOP that addresses planning for pandemic emergencies, scaling down of activities, shutting down, and reopening plans. Conclusions: The ACSR QWG sites now have a structured response SOP for their sites, including guidance on how to develop and implement an emergency shutdown and reopening plan. The complete SOP is publicly available on the ACSR website.
Costal Cartilage Calcification: Prevalence, Amount, and Structural Pattern in the General Population and Its Association with Age: A Cadaveric Study
Hawellek, Thelonius, Beil, Frank Timo , Hischke, Sandra, Saul, Dominik , Hoffmann, D , Kleiss, Sebastian, Rolvien, Tim , Püschel, Klaus , Frosch, Stephan , Hubert, Jan , Hubert, Jan , Saul, Dominik , Ries, Christian

Mayo Clinic

Facial Plastic Surgery & Aesthetic Medicine | October 5, 2021 | Volume: 26 | Issue: 4 | Pages: 481-487

10.1089/fpsam.2021.0063 | PMID 34609907 Get It

Importance: Costal cartilage calcification (CCC) of the cartilage graft, commonly used in reconstruction of nasal/auricular deformities, can cause poor surgical outcome, but structural and quantitative analyses are lacking. Objective: To compare the prevalence, amount, and structural pattern of CCC from individuals by gender and age, as measured by digital contact radiography. Design, Setting, and Participants: This is a cross-sectional cadaveric study ( n = 92) of the seventh rib cartilage. CCC prevalence/amount/structural pattern (central [c]/peripheral [p]/diffuse [d]) was analyzed within three age groups: I (<40 years), II (40–70 years), and III (>70 years). Main Outcomes and Measures: Qualitative and quantitative CCC analyses were set in relation to gender/structural pattern/age. Results: CCC prevalence was gender independent (96.7%) and occurred in c/p/d: 12.4%/22.4%/65.2%. Structural CCC pattern differed between age groups (I: 80%; c/p/d: 26.7%/46.6%/6.7%; II: 100%; c/p/d: 18.0%/30.8%/51.2%; III: 100%; p/d: 2.6%/97.4%). The mean CCC amount (9.1%) was gender independent and showed a significant correlation with age ( p = 0.001). The mean amount showed a significant difference between the structural pattern [d/p: 3.3 times higher ( p = 0.006), d/c: 7.7 times higher ( p < 0.001)] and age groups (I/II/III: 6.4/8.5%/10.9%), whereby the amount was higher in groups II (factor: 7.4; p < 0.001) and III (factor: 16.5; p < 0.001) compared with group I. Conclusions: These data show an age-/gender-independent high CCC prevalence in the general population (96.7%). CCC already occurred in young donors (<40 years) with a not negligible amount (6.4%). CCC increased with age and structural analysis showed a gender-/age-specific pattern, whereby males were prone to peripheral/females to central CCC. Diffuse CCC was observed as an age-independent sign for high CCC levels.
GLI3 Is Stabilized by SPOP Mutations and Promotes Castration Resistance via Functional Cooperation with Androgen Receptor in Prostate Cancer
Burleson, Marieke , Deng, Janice , Qin, Tai, Duong, Thu Minh, Yan, Yuqian , Gu, Xiang , Das, Debodipta , Easley, Acarizia, Liss, Michael A. , Yew, P. Renée , Bedolla, Roble, Kumar, Addanki P. , Huang, Tim H.‐M. , Zou, Yi , Chen, Chun‐Liang , Sun, Lu‐Zhe , Boyer, Thomas , Chen, Yidong , Chen, Chun-Liang , Huang, Rui , Sun, Lu-Zhe , Chen, Yidong , Huang, Haojie

Mayo Clinic

Molecular Cancer Research | October 5, 2021 | Volume: 20 | Issue: 1 | Pages: 62-76

10.1158/1541-7786.mcr-21-0108 | PMID 34610962 Get It

Abstract Although the Sonic hedgehog (SHH) signaling pathway has been implicated in promoting malignant phenotypes of prostate cancer, details on how it is activated and exerts its oncogenic role during prostate cancer development and progression is less clear. Here, we show that GLI3, a key SHH pathway effector, is transcriptionally upregulated during androgen deprivation and posttranslationally stabilized in prostate cancer cells by mutation of speckle-type POZ protein (SPOP). GLI3 is a substrate of SPOP-mediated proteasomal degradation in prostate cancer cells and prostate cancer driver mutations in SPOP abrogate GLI3 degradation. Functionally, GLI3 is necessary and sufficient for the growth and migration of androgen receptor (AR)–positive prostate cancer cells, particularly under androgen-depleted conditions. Importantly, we demonstrate that GLI3 physically interacts and functionally cooperates with AR to enrich an AR-dependent gene expression program leading to castration-resistant growth of xenografted prostate tumors. Finally, we identify an AR/GLI3 coregulated gene signature that is highly correlated with castration-resistant metastatic prostate cancer and predictive of disease recurrence. Together, these findings reveal that hyperactivated GLI3 promotes castration-resistant growth of prostate cancer and provide a rationale for therapeutic targeting of GLI3 in patients with castration-resistant prostate cancer (CRPC). Implications: We describe two clinically relevant mechanisms leading to hyperactivated GLI3 signaling and enhanced AR/GLI3 cross-talk, suggesting that GLI3-specific inhibitors might prove effective to block prostate cancer development or delay CRPC.